Lumida
/ADMA
⌘K
ADMA Biologics Inc

ADMA Biologics Inc

ADMA
$9.23USD-1.70%-0.16 today

MARKET CAP

2.1B

P/E (TTM)

13.4x

FWD P/E

11.6x

DAY RANGE

$9 – $10

52W RANGE

$7
$20

AI Summary

Stalk
Sell NowMedium

ADMA remains rangebound in the lower half of its $8.50–$10.50 corridor with a medium-term bearish bias under declining moving averages. Short-term price sits marginally below the 9- and 20-day EMAs with repeated failures near the 9.60 resistance, favoring sell-side execution on any rally. Given the lack of bullish momentum and presence of distribution characteristics, we recommend selling now on strength around the EMA zone.

  • Ascentive drove total revenue to $124.4M (+2% YoY) with 24% growth
  • Gross margin rose to 69% (from 55%), and adjusted EBITDA climbed 22% to $61.8M
  • Increased supply and pricing pressure may compress immunoglobulin margins
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$80.9M$154.1M$258.2M$426.5M$510.2M
YoY %+91.7%+90.4%+67.6%+65.2%+19.6%
P / Sales2.4x5.0x3.9x9.8x8.8x
EV / Sales3.5x5.7x4.5x9.9x8.9x
Gross Profit, Adj.$1.2M$35.3M$88.9M$219.6M$292.8M
YoY %+106.2%+2906.4%+152.2%+146.8%+33.3%
Margin %1.4%22.9%34.4%51.5%57.4%
EV / Gross Profit239.4x24.8x13.1x19.2x15.5x
EBITDA, Adj.$-52.9M$-32.3M$30.0M$147.0M$199.5M
YoY %+13.3%+39.0%+192.9%+390.7%+35.7%
Margin %-65.3%-20.9%11.6%34.5%39.1%
EV / EBITDA-5.3x-27.2x38.8x28.6x22.7x
EBIT$-58.4M$-39.4M$21.6M$139.0M$191.4M
YoY %+10.1%+32.6%+155.0%+542.5%+37.7%
Margin %-72.1%-25.5%8.4%32.6%37.5%
EV / EBIT-4.8x-22.2x53.7x30.3x23.6x
Net Income$-71.6M$-65.9M$-28.2M$197.7M$146.9M
YoY %+5.4%+8.0%+57.2%+800.0%-25.7%
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (GAAP)-$0.51-$0.33-$0.13$0.81$0.60
YoY %+42.0%+35.3%+60.6%+723.1%-25.9%